← Search another drug
PatientPulse · by PatientPartner
Tysabri natalizumab
High confidence
~58 public patient conversations and reviews referenced across review sites, forums, and personal blogs
Executive intelligence
The signal that moves starts & adherence
55%Positive sentiment in discussion
180,088FDA adverse-event reports
31%Flagged serious
77%Reports name female patients
The single highest-value commercial signal: patients who go JC-positive face a forced switch they dread, and the Ocrevus transition window is the #1 adherence and loyalty battleground for Biogen's own portfolio.
- Tysabri earns near-miraculous effectiveness ratings from highly treatment-experienced MS patients, with 66% reporting positive experience on Drugs.com (7.8/10 average), making it one of the highest-rated MS DMTs in patient-generated reviews.
- PML and JC-virus status dominate the patient decision calculus at initiation and throughout therapy, functioning as a persistent background anxiety that no other MS drug generates at the same emotional intensity.
- End-of-cycle symptom return (days 21-28 pre-infusion) is a widely reported, under-managed lived-experience phenomenon that drives dissatisfaction and calls for a 21-day cycle, yet is absent from clinical talking points.
- Forced switches due to rising JC-antibody titers represent the primary adherence-leak event; patients who must leave Tysabri express grief-like distress, and the transition to Ocrevus is increasingly preferred over oral alternatives by both patients and neurologists.